Optimal stimulation protocols for in vitro fertilization

Fertility and Sterility

Volumn 86, Issue 2, 2006, Pages 267-273

  Muasher, Suheil J ^a,b,c,d   Abdallah, Rony T ^b,d   Hubayter, Ziad R ^b,d  

^a IVF   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

clomiphene citrate; follicle stimulating hormone; gonadotropin releasing hormone agonists and antagonists; gonadotropins; human chorionic gonadotropin; in vitro fertilization; luteinizing hormone; minimal stimulation; Ovarian stimulation

Indexed keywords

BUSERELIN; CETRORELIX; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; FOLLITROPIN; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN DERIVATIVE; GOSERELIN; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; LEUVERIS; LUTEINIZING HORMONE; NAFARELIN ACETATE; NOVAREL; PLACEBO; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; RECOMBINANT HORMONE; RECOMBINANT LUTEINIZING HORMONE; TRIPTORELIN; UNCLASSIFIED DRUG; UROFOLLITROPIN;

CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ESTROGEN DEFICIENCY; FEMALE; FERTILIZATION IN VITRO; HORMONAL REGULATION; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LUTEINIZATION; MEDICAL LITERATURE; OVARY CYST; OVARY HYPERSTIMULATION; PREGNANCY RATE; PRIORITY JOURNAL; PUBLICATION; REVIEW; UNSPECIFIED SIDE EFFECT;

FERTILIZATION IN VITRO; HUMANS; OVULATION INDUCTION;

EID: 33746364541     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2005.09.067     Document Type: Review

References (49)

1. Matorras R., and Rodriguez-Escudero F.G. Debate. Bye-bye urinary gonadotropins?. Hum Reprod 17 (2002) 1675-1683
2. Daya S. Updated meta-analysis of recombinant follicle stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertil Steril 77 (2002) 711-714
3. Al-Inany H., Aboulghar M., Mansour R., and Serour G. Meta-analysis of recombinant versus urinary derived FSH. an update. Hum Reprod 18 (2003) 305-313
4. European and Israeli Study Group. Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles. a randomized, comparative trial. Fertil Steril 78 (2002) 520-528
5. Dickey R.P., Thornton M., Nichols J., Marshall D.C., Fein S.H., and Nardi R.V. Comparison of the efficacy and safety of a highly purified human follicle-stimulating hormone (Bravelle) and recombinant follitropin-beta for in vitro fertilization. a prospective, randomized study. Fertil Steril 77 (2002) 1202-1208
6. Van Wely M., Westergaard L., Bossuyt P., and Van Der Veen M. Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles. a meta-analysis. Fertil Steril 80 (2003) 1086-1093
7. Lloyd A., Kennedy R., Hutchison J., and Sawyer W. Economic evaluation of highly purified menotropin compared with recombinant follicle stimulating hormone in assisted reproduction. Fertil Steril 80 (2003) 1108-1113
8. Agrawal R., Holmes J., and Jacobs H.S. Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles. a meta-analysis. Fertil Steril 73 (2000) 338-343
9. Filicori M. Use of luteinizing hormone in the treatment of infertility: time for reassessment? Fertil Steril 20003;79:253-5.
10. Filicori M., Cognogni G.E., Tabarelli C., Pocognoli P., Taraborrelli S., Spettoli D., and Ciampaglia W. Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. J Clin Endocrinol Metab 87 (2002) 1156-1161
11. Filicori M., Cognigni G.E., Taraborrelli S., Spettoli D., Ciampaglia W., Tabarelli De Fatis C., et al. Luteinizing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. J Clin Endocrinol Metab 86 (2001) 337-343
12. Kilani Z., Dakkak A., Ghunaim S., Cognigni G., Tabarelli C., Parmegiani L., and Fililori M. A Prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI. ovarian response and clinical outcomes. Hum Reprod 18 (2003) 1194-1199
13. Prato L., Borini A., Coticchio G., Cattoli M., and Flamigni C. Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology. a randomized study. Hum Reprod 19 (2004) 2200-2205
14. Simons A.H.M., Roelofs H., Schmoutzigner A., Roozenburg B., Van't Hof-Van den Brink E., and Schoonderwoerd S. Early cessation of triptorelin in in vitro fertilization. a double-blind randomized study. Fertil Steril 83 (2005) 889-896
15. Ben-Amor A.F. The effect of luteinizing hormone administered during late follicular phase in normal ovulatory women undergoing IVF. Hum Reprod 15 (2000) 46-52
16. Tesarik J., and Mendoza C. Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence. Hum Reprod 17 (2002) 3129-3137
17. Marr R., Meldrum D., Muasher S., Schoolcraft W., Werlin L., and Kelly E. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod Biomed Online 8 (2004) 175-182
18. Cabrera R., Stadtmauer L., Mayer J., Gibbons W., and Oehninger S. Follicle phase serum levels of luteinizing hormone do not influence delivery rates in in-vitro fertilization cycles down-regulated with a gonandotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone. Fertil Steril 83 (2005) 42-48
19. Tesarik J., Hazont A., and Mendoza C. Enhancement of embryo development potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod 19 (2004) 1176-1180
20. Tersarik, Hazont A., and Mendoza C. Luteinizing hormone affects uterine receptivity independently of ovarian function. Reprod Biomed Online 7 (2003) 59-64
21. European Orgalutran Study Group. A double blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to event premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group. Hum Reprod 13 (1998) 3023-3031
22. European Orgalutran Study Group. Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient. results of a controlled, randomized, multicentre trial. Human Reprod 15 (2000) 1490-1498
23. European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 16 (2001) 644-651
24. North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 75 (2001) 38-45
25. Ludwig M., Katalinic A., and Diedrich K. Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet 265 (2001) 175-182
26. Al-Inany H., and Aboulghar M. GnRH antagonist in assisted reproduction. a Cochrane review. Hum Reprod 17 (2002) 874-885
27. Akman M.A., Erden H.F., Tosun S.B., Bayazit N., Aksoy E., and Bahceci M. Comparison of agonistic flare-up protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders. results of a prospective randomized trial. Hum Reprod (2001) 868-870
28. Mohamed K., Davies W., Allsopp J., and Lashen H. Agonist "flare up" versus antagonist in the management of poor responders undergoing in-vitro fertilization treatment. Fertil Steril 83 (2005) 331-335
29. Cheung L.-P., Lok I., Chiu T., Yeung S.-Y., Tjer C.-C., and Haines C. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF. a randomized controlled trial. P.-M. Hum Reprod 20 (2005) 616-621
30. Acevedo B., Sanchez M., Gomez J.L., Cuadros J., Ricciarelli E., and Hernandez E. Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles. Fertil Steril 82 (2004) 343-347
31. Cedrin-Durnerin I., Grange-Dujardin D., Luffy A., Parneix I., Massin N., Galey J., et al. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles. a prospective randomized study. Hum Reprod 19 (2004) 1979-1984
32. Griesinger G., Schultze-Mosgan A., Dafapoulos K., Schroedor A., Schroer A., Otte S., et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple dose protocol. Hum Reprod 20 (2005) 1200-1206
33. Ludwig M., Katalinic A., Banz C., Schroder A.K., Loning M., Weiss J.M., and Diedrich K. Tailoring the GnH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF. results of a prospective, randomized study. Hum Reprod (2002) 2842-2845
34. Mochtar M. The effect of an individualized GnRH antagonist protocol in folliculogensis in IVF/ICSI. Hum Reprod 19 (2004) 1714-1718
35. Kolibianakis E., Albano C., Camus M., Toymaye H., Van Steirteghem A., and Devroey P. Prolongation of the follicular phase in in-vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril 82 (2004) 102-107
36. Itskovitz-Eldor J., Kol S., and Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod 15 (2000) 1965-1968
37. Fauser B.C., de Jong D., Olivennes F., Wramby H., Tay C., Itskovotz-Eldor J., and van Hooren H.G. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 87 (2002) 709-715
38. Humaidan P., Bredkjaer H., Bungum L., Bungum M., Grondahl M., Westergaard L., and Andersen C. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles. a prospective randomized study. Hum Reprod 20 (2005) 1213-1220
39. Shamma F., Grossman P., Abuzeid M., al-Hosn L., Ayers J., and Fakih M. Comparison of daily ganirelix administration to a long protocol agonist for controlled ovarian hyperstimulation in oocyte donors. the results of a prospective randomized controlled trial. Fertil Steril 80 Suppl 3 (2003) S37
40. Prapas N., Prapas Y., Panagiotidis Y., Prapa S., Vanderzwalmen P., Schoysman R., and Makedos G. GnRH agonist versus GnRH antagonist in oocyte donation cycles. a prospective randomized study. Hum Reprod 20 (2005) 1516-1520
41. Seelig A.S., Al-Hasani S., Katalinic A., Schopper B., Strum R., Diedrich K., and Ludwig M. Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle. Fertil Steril 77 (2002) 472-475
42. Williams D.C., Gibbons W.E., Muasher S.J., and Oehninger S. Minimal ovarian hyperstimulation for in vitro fertilization using sequential clomiphene citrate and gonadotropin with or without the addition of a gonadotropin-releasing hormone antagonist. Fertil Steril 78 (2002) 1068-1072
43. Weigert M., Krischker U., Pohl M., Poschalko G., Kindermann C., and Feichtinger W. Comparison of stimulation with clomiphene citrate in combination with recombinant follicle stimulation with a gonadotropin-releasing hormone agonist protocol. a prospective, randomized study. Fertil Steril 78 (2002) 34-39
44. Engel J.B., Ludwig M., Felberbaum R., Albano C., Devroey P., and Diedrich K. Use of cetrorelix in combination with clomiphene citrate and gonadotropins. a suitable approach to "friendly IVF"?. Hum Reprod 17 (2002) 2022-2026
45. Hwang J.L., Huang L.W., Hsieh B.C., Tsai Y.L., Huang S.C., Chen C.Y., et al. Ovarian stimulation by clomiphene citrate and hMG in combination with centrorelix acetate for ICSI cycles. Hum Reprod 18 (2003) 45-49
46. D'Amato G., Caroppo E., Pasquadibisceglie A., Carone D., Vitti A., and Viziello G. A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35. Fertil Steril 81 (2004) 1572-1577
47. Weghofer A., Margreiter M., Bassim S., Selveda U., Beiehack E.K., and Feichtinger W. Minimal stimulation using recombinant follicle-stimulating hormone and a gonadotropin-releasing hormone antagonist in women of advanced age. Fertil Steril 81 (2004) 1002-1006
48. Hurst B.S., Tucker K.E., and Schlaff W.D. A minimally monitored assisted reproduction stimulation protocol reduces cost without compromising success. Fertil Steril 77 (2002) 98-100
49. Pelinck M., Vogel N., Hoek A., Arts E., Simons A., and Heineman M. Minimal stimulation IVF with late follicular phase administration of GnRH antagonist cetrorelix and concomitant substitution with recombinant FSH, a pilot study. Hum Reprod 20 (2005) 642-648